SAGE SAGE THERAPEUTICS INC Operational Disruptions 8-K Filing 2024 - Phase 2 Study Results Sage Therapeutics and Biogen announce topline results from Phase 2 study of SAGE-324 for the treatment of Essential Tremor.Get access to all SEC 8-K filings of the SAGE THERAPEUTICS INC